Ocular Therapeutix Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 9.1% | 9.4% | 9.0% | 9.2% | 10.1% | 7.2% | 11.8% | 14.4% | 12.2% | 12.0% | 12.3% | 14.9% | 12.9% | |
| 90.9% | 90.6% | 91.0% | 90.8% | 89.9% | 92.8% | 88.2% | 85.6% | 87.8% | 88.0% | 87.7% | 85.1% | 87.1% | |
| 99.6% | 109.4% | 140.3% | 175.5% | 240.2% | 240.0% | 400.6% | 379.5% | 360.0% | 383.4% | 613.9% | 401.8% | 429.4% | |
| 112.0% | 295.6% | 156.1% | 119.6% | 79.3% | 141.2% | 270.5% | 197.3% | 110.2% | 133.3% | 185.5% | 164.4% | 145.7% | |
| 218.3% | 226.1% | 305.0% | 356.0% | 388.1% | 388.9% | 685.7% | 588.1% | 560.1% | 614.5% | 953.1% | 694.4% | 690.2% | |
| -127.4% | -135.5% | -214.0% | -265.1% | -298.2% | -296.1% | -597.5% | -502.6% | -472.3% | -526.5% | -865.5% | -609.3% | -603.0% | |
| 22.7% | 28.0% | 27.4% | 19.4% | 20.9% | 18.2% | 27.9% | 22.4% | 20.6% | 21.4% | 25.7% | 20.7% | 21.9% | |
| -3.4% | -197.4% | -438.9% | -266.3% | -236.6% | -283.3% | -598.7% | -503.9% | -477.3% | -488.0% | -821.6% | -584.5% | -579.1% | |
| -5.9% | -48.5% | -6.2% | – | – | – | – | – | – | – | – | – | – | |
| -3.4% | -197.4% | -438.9% | -266.3% | -236.6% | -283.3% | -598.7% | -503.9% | -477.3% | -488.0% | -821.6% | -584.5% | -579.1% | |
| 25.2% | -162.9% | -405.3% | -241.0% | -209.5% | -259.5% | -561.7% | -473.8% | -449.3% | -457.2% | -784.0% | -550.1% | -546.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.